Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Zosyn® (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer’s solutions and selected aminoglycosides

Authors Narendra R Desai, Syed M Shah, Jonathan Cohen, Matthew McLaughlin, Hema R Dalal

Published 11 April 2008 Volume 2008:4(2) Pages 303—314

DOI https://doi.org/10.2147/TCRM.S2564

Narendra R Desai, Syed M Shah, Jonathan Cohen, Matthew McLaughlin, Hema R Dalal

Formulation Development, Wyeth Research, Pearl River, NY, USA

Abstract: Zosyn®, also known as Tazocin® for injection, contains piperacillin and tazobactam and was approved by the US Food and Drug Administration in 1993 for the treatment of indicated serious infections. In 1995, United States Pharmacopoeia and European Pharmacopoeias reduced the particulate limit for injectables by 40%, based on general safety concerns. Wyeth attempted to control sporadic batch failures (associated with increased particulate formation) by shortening product expiration dating from 36 to 24 months and optimizing the stopper siliconization process. These modifications did not correct the problem completely. Wyeth reformulated Zosyn by incorporating two stabilizing functional excipients, ethylene diamine tetraacetic acid disodium salt (EDTA disodium) and sodium citrate, which solved the particulate formation problem. These two functional excipients also allowed for the first time Y-site coadministration of reformulated Zosyn product with amikacin and gentamicin at specific doses and concentrations, and with certain diluents, and the use of Ca++ ion-containing Lactated Ringer’s for admixture preparation. Reformulated Zosyn (approved 2005) may provide useful options of drug administration to healthcare professionals to lessen levels of particulates. Supportive data is provided for the expanded compatibility of reformulated Zosyn with different types of Ringer’s solutions used globally and for the Y-site coadministration of amikacin and gentamicin aminoglycosides.

Keywords: Zosyn®, aminoglycoside, piperacillin, particulate matter

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Fospropofol disodium injection for the sedation of patients undergoing colonoscopy

Benjamin E Levitzky, John J Vargo

Therapeutics and Clinical Risk Management 2008, 4:733-738

Published Date: 8 August 2008

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Therapeutics and Clinical Risk Management 2008, 4:821-826

Published Date: 8 August 2008

Enfuvirtide antiretroviral therapy in HIV-1 infection

Christina MR Kitchen, Miriam Nuño, Scott G Kitchen, Paul Krogstad

Therapeutics and Clinical Risk Management 2008, 4:433-439

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:361-362

Published Date: 15 July 2007